Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25 transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Carter Denise P. | Director, Chief Operating Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 20,490 | $4.88 | $99,991.20 | 37,709Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Lawlor Sally Bridget | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 10,244 | $4.88 | $49,990.72 | 10,684Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Myers Michael | Director, Chief Executive Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 20,490 | $4.88 | $99,991.20 | 37,713Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Culverwell Anthony James | Director | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 6,146 | $4.88 | $29,992.48 | 40,364Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| Culverwell Anthony James | Director | Quoin Pharmaceuticals Ltd.QNRX | OtherA · Grant or award from the company | 31,352 | $5.15 | $161,462.80 | 34,218Direct | Form 4 filed 28 Aug 2026, on sec.gov (opens in a new tab)Filed 28 Aug 2026 | |
| LANGER DENNIS | Director | Quoin Pharmaceuticals Ltd.QNRX | OtherA · Grant or award from the company | 34,534 | $5.15 | $177,850.10 | 56,243Direct | Form 4 filed 28 Aug 2026, on sec.gov (opens in a new tab)Filed 28 Aug 2026 | |
| LANGER DENNIS | Director | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 15,152 | $8.49 | $128,640.48 | 15,153Direct | Form 4 filed 15 Oct 2025, on sec.gov (opens in a new tab)Filed 15 Oct 2025 | |
| Culverwell Anthony James | Director | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 100,000 | $0.45 | $45,000 | 100,317Direct | Form 4 filed 27 Dec 2024, on sec.gov (opens in a new tab)Filed 27 Dec 2024 | |
| Dunn Gordon | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 122,221 | $0.45 | $54,999.45 | 151,077Direct | Form 4 filed 27 Dec 2024, on sec.gov (opens in a new tab)Filed 27 Dec 2024 | |
| Carter Denise P. | Director, Chief Operating Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 555,556 | $0.45 | $250,000.20 | 602,648Direct | Form 4 filed 27 Dec 2024, on sec.gov (opens in a new tab)Filed 27 Dec 2024 | |
| Myers Michael | Director, Chief Executive Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 555,556 | $0.45 | $250,000.20 | 602,808Direct | Form 4 filed 27 Dec 2024, on sec.gov (opens in a new tab)Filed 27 Dec 2024 | |
| Dunn Gordon | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 10,000 | $0.71 | $7,100 | 28,856Direct | Form 4 filed 11 Sep 2024, on sec.gov (opens in a new tab)Filed 11 Sep 2024 | |
| Dunn Gordon | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 10,000 | $0.91 | $9,100 | 18,856Direct | Form 4 filed 11 Sep 2024, on sec.gov (opens in a new tab)Filed 11 Sep 2024 | |
| Dunn Gordon | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 4,000 | $0.80 | $3,200 | 8,856Direct | Form 4 filed 11 Sep 2024, on sec.gov (opens in a new tab)Filed 11 Sep 2024 | |
| Dunn Gordon | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 4,000 | $0.78 | $3,120 | 4,856Direct | Form 4 filed 11 Sep 2024, on sec.gov (opens in a new tab)Filed 11 Sep 2024 | |
| Dunn Gordon | Chief Financial Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 856 | $0.80 | $684.80 | 856Direct | Form 4 filed 11 Sep 2024, on sec.gov (opens in a new tab)Filed 11 Sep 2024 | |
| Myers Michael | Director, Chief Executive Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 23,572 | $0.80 | $18,857.60 | 47,252Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Myers Michael | Director, Chief Executive Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 8,200 | $0.75 | $6,150 | 23,680Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Myers Michael | Director, Chief Executive Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 5,322 | $0.66 | $3,512.52 | 15,480Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Carter Denise P. | Director, Chief Operating Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 22,988 | $0.80 | $18,390.40 | 47,092Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Carter Denise P. | Director, Chief Operating Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 8,825 | $0.75 | $6,618.75 | 24,104Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Myers Michael | Director, Chief Executive Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 800 | $0.62 | $496 | 10,158Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Carter Denise P. | Director, Chief Operating Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 4,100 | $0.66 | $2,706 | 15,279Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| Carter Denise P. | Director, Chief Operating Officer | Quoin Pharmaceuticals Ltd.QNRX | BuyP · Open-market or private purchase | 1,822 | $0.63 | $1,147.86 | 11,179Direct | Form 4 filed 5 Sep 2024, on sec.gov (opens in a new tab)Filed 5 Sep 2024 | |
| LANGER DENNIS | Director | Quoin Pharmaceuticals Ltd.QNRX | SellS · Open-market or private sale | 297 | $0.73 | $216.81 | 53Direct | Form 4 filed 10 Jun 2024, on sec.gov (opens in a new tab)Filed 10 Jun 2024 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.